Abstract
In this issue of Urology, Wymer et al report on the cost effectiveness of different surgical treatment strategies for benign prostatic hyperplasia (BPH) as measured by Medicare cost, quality-adjusted life years, and incremental cost-effective ratios at 5 years after surgery. Specifically, they compared holmium laser enucleation of the prostate (HoLEP), bipolar transurethral resection of the prostate (B-TURP), water vapor thermal therapy (WVTT), and prostatic urethral lift (PUL) for prostates under 80 g and HoLEP versus simple prostatectomy (SP) for glands larger than 80 grams.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
